MA56215A - Traitement topique du vitiligo par un inhibiteur de jak - Google Patents

Traitement topique du vitiligo par un inhibiteur de jak

Info

Publication number
MA56215A
MA56215A MA056215A MA56215A MA56215A MA 56215 A MA56215 A MA 56215A MA 056215 A MA056215 A MA 056215A MA 56215 A MA56215 A MA 56215A MA 56215 A MA56215 A MA 56215A
Authority
MA
Morocco
Prior art keywords
vitiligo
topical treatment
jak inhibitor
jak
inhibitor
Prior art date
Application number
MA056215A
Other languages
English (en)
Inventor
Kathleen Butler
Michael Howell
Fiona Kuo
Jim Lee
Kang Sun
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73651112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA56215(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA56215A publication Critical patent/MA56215A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056215A 2019-06-10 2020-06-10 Traitement topique du vitiligo par un inhibiteur de jak MA56215A (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962859584P 2019-06-10 2019-06-10
US201962859495P 2019-06-10 2019-06-10
US201962859601P 2019-06-10 2019-06-10
US201962859506P 2019-06-10 2019-06-10
US201962859532P 2019-06-10 2019-06-10
US201962894496P 2019-08-30 2019-08-30
US201962894514P 2019-08-30 2019-08-30
US201962894541P 2019-08-30 2019-08-30
US201962894581P 2019-08-30 2019-08-30
US201962894564P 2019-08-30 2019-08-30
US201962911845P 2019-10-07 2019-10-07
US202062967879P 2020-01-30 2020-01-30

Publications (1)

Publication Number Publication Date
MA56215A true MA56215A (fr) 2022-04-20

Family

ID=73651112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056215A MA56215A (fr) 2019-06-10 2020-06-10 Traitement topique du vitiligo par un inhibiteur de jak

Country Status (9)

Country Link
US (4) US11602536B2 (fr)
EP (1) EP3982971A4 (fr)
JP (2) JP7532511B2 (fr)
AU (2) AU2020290995B2 (fr)
CA (1) CA3150975A1 (fr)
IL (1) IL290637A (fr)
MA (1) MA56215A (fr)
TW (1) TW202112377A (fr)
WO (1) WO2020252012A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
CN112823005B (zh) 2018-08-10 2024-08-20 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
WO2020252012A1 (fr) 2019-06-10 2020-12-17 Incyte Corporation Traitement topique du vitiligo par un inhibiteur de jak
WO2022061351A1 (fr) * 2020-09-16 2022-03-24 Incyte Corporation Traitement topique du vitiligo
TW202302104A (zh) * 2021-02-18 2023-01-16 美商阿克拉里斯醫療股份有限公司 Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法
EP4389114A4 (fr) * 2021-08-19 2025-09-03 Zhuhai United Laboratories Co Ltd Formulation topique locale contenant un inhibiteur de jak ou un sel de celui-ci ou une forme cristalline de celui-ci, procédé de préparation associé et application correspondante
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2000009495A1 (fr) 1998-08-11 2000-02-24 Novartis Ag Derives d'isoquinoline possedant une activite d'inhibition de l'angiogenese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
MXPA04002243A (es) 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
EP3070090B1 (fr) 2007-06-13 2018-12-12 Incyte Holdings Corporation Utilisation des sels de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
RU2019117562A (ru) 2016-11-10 2020-12-10 Галапагос Нв Соединения и их фармацевтические композиции для лечения воспалительных заболеваний
WO2018200786A1 (fr) 2017-04-26 2018-11-01 Yale University Compositions et méthodes pour traiter le vitiligo
US20190060311A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
EP3775284A1 (fr) 2018-03-30 2021-02-17 Incyte Corporation Biomarqueurs pour maladie cutanée inflammatoire
CN111374639A (zh) 2018-12-28 2020-07-07 陈柏龄 败血症的菌种预测系统与方法
WO2020252012A1 (fr) * 2019-06-10 2020-12-17 Incyte Corporation Traitement topique du vitiligo par un inhibiteur de jak
US20210030672A1 (en) 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor

Also Published As

Publication number Publication date
JP7532511B2 (ja) 2024-08-13
AU2026200410A1 (en) 2026-02-12
EP3982971A1 (fr) 2022-04-20
EP3982971A4 (fr) 2023-08-16
JP2022545568A (ja) 2022-10-27
IL290637A (en) 2022-04-01
US20200405627A1 (en) 2020-12-31
AU2020290995B2 (en) 2025-12-11
US12233067B2 (en) 2025-02-25
US11590138B2 (en) 2023-02-28
US20200383986A1 (en) 2020-12-10
US20230355628A1 (en) 2023-11-09
JP2024105436A (ja) 2024-08-06
US20220409622A1 (en) 2022-12-29
AU2020290995A1 (en) 2022-04-07
TW202112377A (zh) 2021-04-01
CA3150975A1 (fr) 2020-12-17
WO2020252012A1 (fr) 2020-12-17
US11602536B2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
MA56215A (fr) Traitement topique du vitiligo par un inhibiteur de jak
IL285662A (en) Use of cannabinoids in the treatment of epilepsy
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
EP4125884A4 (fr) Combinaisons d'inhibiteurs d'eif4a
DK3932919T3 (da) Jak-inhibitorforbindelse og anvendelse deraf
EP4495113A4 (fr) Inhibiteur de kif18a
SI3773593T1 (sl) Zdravljenje hidradenitisa suppurative z zaviralci jak
EP4434979A4 (fr) Inhibiteur de kif18a
MA54622A (fr) Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
EP3937964A4 (fr) Traitement de cancers induits par des oncogènes
IL287904A (en) Combination treatment of arthritic disease
MA52627A (fr) Traitement du cancer
EP4493175A4 (fr) Traitement à base de mirdamétinib
IL308335A (en) Combination therapies
EP3737383A4 (fr) Traitement synergique du cancer
EP3966209A4 (fr) Inhibiteurs de jak
IL285020A (en) Topical phosphoinositide 3-kinase inhibitors
EP4168398A4 (fr) Inhibiteur de tyk -2
JP1778652S (ja) マッサージ器
IL291424A (en) Use of dkk-1 inhibitors for treating cancer
EP4319748A4 (fr) Traitement du cancer par des inhibiteurs de kdm4
EP3833378A4 (fr) Traitement des verrues
EP4424177A4 (fr) Inhibiteur de prolifération du sars-cov-2
EP3986109C0 (fr) Traitement au plasma
EP4469458A4 (fr) Inhibiteurs de la kallicréine plasmatique